Journal article
Anticipating Near-Term Shifts in the Outsourcing Landscape
Applied clinical trials, Vol.33(1/2), pp.16-21
01 Jan 2024
Abstract
The early resistance to FSP from CROs was primarily driven out of fear of cannibalizing their full-service business and margin erosion as a result of what they viewed as a "race to the bottom." [...]in the early 2000s, FSP providers came along to offer necessary variability within pharma's internal workforce. In essence, these "must-have" capabilities beyond clinical trial design include areas such as start-up activities, patient engagement, statistical analysis, and even field forces that cultivate close connections with investigators and data management with a single operating platform providing readily accessible data. Case-in-point, Merck's in-house clinical development model was recently seen as a competitive advantage for patient accrual over its industry peers, as evidenced in Figure 1 (see facing page) from the British Medical Journal article published in 2022. Since the publication of this article, several of the comparator pharma companies listed in the report have largely switched their sourcing strategy from FSO to FSP, further validating interest in enhancing the in-house capability to be able to compete.
Metrics
12 Record Views
Details
- Title
- Anticipating Near-Term Shifts in the Outsourcing Landscape
- Creators
- Samir Shah
- Publication Details
- Applied clinical trials, Vol.33(1/2), pp.16-21
- Publisher
- MultiMedia Healthcare Inc
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Decision Sciences (and Management Information Systems)
- Identifiers
- 991021860111104721